53839-60-4

Basic information

• Product Name: Retinoyl chloride
• Synonyms: Retinoyl chloride;OBWAFSRXIGEEKA-YCNIQYBTSA-N
• CAS NO: 53839-60-4
• Molecular Formula: C₂₀H₂₇ClO
• Molecular Weight: 318.88078
• EINECS: -0
• Mol File: 53839-60-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Retinoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: Retinoyl chloride(53839-60-4)
• EPA Substance Registry System: Retinoyl chloride(53839-60-4)

Safety Data

• Hazardous Substances Data: 53839-60-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Retinoyl chloride is used as an intermediate in the synthesis of retinyl ascorbate (RA-AsA) for the purpose of treating skin damage resulting from UV-induced production of free radicals. RA-AsA is a co-drug that combines the benefits of vitamin A and vitamin C, offering enhanced antioxidant and skin protective properties.
Used in Cosmetic Industry:
Retinoyl chloride is also used as a precursor in the production of cosmetic ingredients, such as retinyl esters, which are known for their anti-aging and skin rejuvenation properties. These esters are more stable and less irritating than retinoic acid, making them suitable for use in skincare products.

Upstream product

• 186581-53-3 diazomethane 
• 302-79-4 all-trans-retinoic-acid 
• 98300-76-6 2,3,4,6-tetra-O-acetylglucopyranosyl 1-amine 
• 7664-93-9 sulfuric acid 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 302-79-4 9-cis-retinoic acid 
• 7719-12-2 phosphorus trichloride 
• 60-29-7 diethyl ether 
• 57-88-5 cholesterol 
• 1126-81-4 4-acetamidothiophenol 

Downstream Products

• 65646-90-4 N-n-Propyl all-trans-retinamide 
• 110683-04-0 N-(all-trans-retinoyl)-L-alanine ethyl ester 
• 110683-08-4 N-(all-trans-retinoyl)glutamic acid diethyl ester 
• 58175-89-6 retinoic anhydride 
• 110683-03-9 N-(all-trans-retinoyl)-L-phenylalanine methyl ester 
• 110683-06-2 N-(all-trans-retinoyl)-DL-tyrosine ethyl ester 
• 125780-97-4 3'-azido-3'-deoxy-5'-O-retinoylthimidine 
• 158419-87-5 (2,3,4-Tri-O-acetyl-β-D-xylopyranosyl)-4-retinamidophenylmethane 
• 158419-78-4 1-(2,3,4-Tri-O-acetyl-β-D-xylopyranosyl)-4-retinamidobenzene 
• 158419-74-0 1-(Methyl 2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-4-retinamidobenzene 
• 158419-85-3 (Methyl 2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate)-4-retinamidophenylmethane 
• 158419-80-8 (2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-4-retinamidophenylmethane 
• 65646-68-6 N-(4-hydroxyphenyl)-all-trans-retinamide 
• 33631-42-4 all-trans-N-Methylretinamide 

Relevant articles and documents

Synthesis and comparative anti-HIV activities of new acetylated 2',3'-dideoxy-3'-thiacytidine analogues

A series of prodrugs of 2',3'-dideoxy-3'-thiacytidine have been synthesized in an effort to enhance the uptake of the prodrugs by HIV-1 infected cells and to increase the plasma half-life.The anti-HIV 1 activities of the new analogues and their cytotoxici

COSMETIC COMPOSITION FOR SKIN WHITENING COMPRISING RETINOIDS DERIVATIVE AS ACTIVE INGREDIENT

PURPOSE: A cosmetic composition containing a retinoid derivative as an active ingredient is provided to suppress tyrosinase activity and melanogenesis. CONSTITUTION: A composition for skin whitening contains 0.001-10 wt% of a retinoid derivative of chemic

Retinoid Compounds containing ATP and preparing method thereof

The present invention relates to a retinoid compound containing adenosine triphosphate (ATP) and a preparation method thereof and, more specifically, to a retinoid compound containing ATP, capable of improving functionality and securing stability by bondi

Podophyllotoxin-retinoic acid heterocomplex synthesis method and application of podophyllotoxin-retinoic acid heterocomplex in medicine for preventing and curing tumors

The invention relates to a podophyllotoxin-retinoic acid heterocomplex synthesis method and application of a podophyllotoxin-retinoic acid heterocomplex in a medicine for preventing and curing tumors. The podophyllotoxin-retinoic acid heterocomplex has a

Retinoid Compounds containing norepinephrine and preparing method thereof

The present invention relates to a retinoid compound containing norepinephrine and to a manufacturing method thereof, and more particularly, to a retinoid compound containing norepinephrine, capable of improving functionality of retinoic acid and minimizi

Synthesis of retinoid analogues of juvenile hormones

As part of a collaborative research project aimed at designing new chemicals active on mosquito larvae, we sought accessible raw materials and an efficient synthesis method for preparing large amounts of active substances. For this we selected retinoic ac

RETINOID DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumours, such as acute leukemia, chronic leukemia, multiple myeloma and lymphom

Retinoid Derivative and Pharmaceutical Composition and Use Thereof

The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumours, such as acute leukemia, chronic leukemia, multiple myeloma and lymphom

Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs

Using solid phase-assisted synthesis and purification, a 49 member library of analogs of the mammary tumor chemopreventive retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been prepared. After prescreening for growth inhibitory activity in human mammary tumor cells (MCF-7) in culture, most of those analogs which showed activity (12 of them) were assayed for apoptosis-inducing activity in the MCF-7 cells. At least 3 of the analogs (13, 24, and 28) showed activity approaching that of 4-HPR.

Synthesis and biological activity of novel retinamide and retinoate derivatives

Retinoic acid and its amide derivative, N-(4-hydroxyphenyl)retinamide (4-HPR), have been proposed as chemopreventative and chemotherapeutic agents. However, their low cytotoxic activity and water solubility limit their clinical use. In this study, we synthesized novel retinoid derivatives with improved cytotoxicity against cancer cells and increased hygroscopicity. Our syntheses were preceded by selective O-acylation and N-acylation, which led to the production of retinoate and retinamide derivatives, respectively, in one pot directly from aminophenol derivatives and retinoic acid without protection. Transcription assays in COS-1 cells indicated that the N-acylated derivatives (2A - 5A) and 4-HPR (1A) were much weaker ligands for all three subtypes of retinoic acid receptor (RAR) than all-trans retinoic acid (ATRA), although they showed some selectivity for RARβ and RARγ. In contrast, the O-acylated retinoate derivatives (1B - 5B) activated all three RAR isotypes without specificity to an extent similar to ATRA. The cytotoxicity was determined using an MTT assay with HCT116 colon cancer cells, and the IC 50 of N-acylated retinamide derivative 4A and O-acylated retinoate derivative 5B was 1.67 μM and 0.65 μM, respectively, which are about five and 13-fold better than that of 4-HPR (8.21 μM), a prototype N-acylated derivative. When retinoate derivative 5B was coupled to organic acid salts, the resulting salt derivatives 5C and 5D had RAR activation and cytotoxicity similar to those of 5B. These data may delineate the relationship between the structure and function of retinoate and retinamide derivatives.